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Now that a number of genomes have been
sequenced, attention has turned to understanding
the complement of proteins encoded by the genome,
which has been termed the ‘proteome’. One impor-
tant aspect of analysis of the proteome is the
identiﬁcation of which proteins interact with each
other; this information is invaluable in surmising
the function of each protein and inferring what
cellular pathway the protein may be a component
of. While a variety of methodologies is widely used
to map protein-protein interactions, such as afﬁnity
puriﬁcation followed by mass spectrometry and
yeast two-hybrid screening (both of which were
covered at this meeting), an alternative approach is
the use of phage-displayed combinatorial peptides.
In phage-display, short oligonucleotides are
inserted within a gene encoding a capsid (coat)
protein of a bacteriophage, so that each viral part-
icle displays a different peptide sequence. While
it has been possible to clone and express short
peptides attached to each of the ﬁve different capsid
proteins of bacteriophage M13, the protein pro-
ducts of gene III and VIII are popular cloning sites
for expression and display. Several excellent reviews
of phage-display can be found elsewhere [6,22,5].
Over the past ten years, a considerable number of
phage-displayed combinatorial peptide libraries
have been generated [21].
With a library of recombinant phage particles
in hand, it is possible to screen them by afﬁnity
selection with a variety of protein targets. Three
rounds of selection (binding, elution, propagation)
are typically sufﬁcient to screen billions of different
phage-displayed combinatorial peptides for those
that bind to target proteins of interest. While there
have been many recent publications of successful
selection experiments, some of the more notable
examples are the selection of peptide ligands which
bind to receptors for erythropoietin [30], N-methyl
D-aspartate (NMDA) [16], thrombopoietin [7],
ﬁbroblast growth factor [3], and estrogen [17].
When peptides are chemically synthesized corre-
sponding to what is displayed by the selected phage,
they generally bind with dissociation constant (Kd)
values of 5 micromolar to 10 nanomolar to their
cognate receptor, and typically have agonist or
antagonist activities. Many different types of targets
will yield phage after afﬁnity selection, such as
enzymes [12], growth factors [10,4], nucleic acids [2],
and cells [20,13].
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tion, cellular differentiation, and apoptosis have
been used in phage-display selection experiments.
Because of their central roles in cell physiology,
understanding the function of these proteins has
included mapping the proteins that they interact
with in the cell. As was described at the recent ESF
Workshop in Rome, one can select peptide ligands
for such targets from phage-displayed combinator-
ial peptide libraries and then use the consensus
among the selected peptides to predict what the
target protein might bind in the cell. Surprisingly,
the consensus often resembles a primary structure
within the natural interacting partner of the protein;
we have termed this phenomenon ‘convergent
evolution’ [14]. Thus, a fruitful approach for
mapping protein-protein interactions is to isolate
peptide ligands to a target protein and then iden-
tify candidate interacting proteins in a sequenced
genome by computer analysis.
Several examples were presented at the meeting.
One example involved the two Eps15 Homology
(EH) domains of the adaptor protein, intersectin
[31], which is involved in endocytosis [18,25] and
signal transduction [1,28]. Afﬁnity selection of
peptides that bound to these two domains identiﬁed
the motif, Asp-Pro-Phe (NPF), as their optimal
ligands [31], much like other EH domains [23,19].
This tripeptide motif is repeated several times in
other protein components of the endocytic machin-
ery and suggests a speciﬁc network of multivalent
protein-protein interaction in endocytosis and
membrane trafﬁcking [24]. Recently, a three-
dimensional structure of an NPF peptide com-
plexed to an EH domain has been solved by NMR
spectroscopy [8], which veriﬁed that the NPF
residues form a b-turn that contacts the surface of
the EH domain. Another example presented
involved the N-terminal Src Homology 3 (SH3)
domain of intersectin. When a phage-displayed
combinatorial peptide library was afﬁnity selected
with this domain, the resulting peptides shared the
motif Pro-Xxx-Ile/Val-Pro-Pro-Arg (PxI/VPPR),
where Xxx appears to be any amino acid. A computer
search of mammalian proteins in GenBank revealed a
number of interest-
ing matches, including dynamin, synaptojanin, and
Son-of-sevenless (Sos). While dynamin and/or synapto-
janin were already reported to interact with inter-
sectin in pull-down [31], yeast two-hybrid [25], and
co-immunoprecipitation [18] experiments, Sos was
considered to be an interesting candidate interacting
protein because it functions to stimulate GTP
loading and activation of Ras [9]. A variety
of subsequent experiments conﬁrmed that the
N-terminal SH3 domain of intersectin interacted
with Sos, and that overexpression in cells of this
SH3 domain could block Ras activation and down-
stream signaling events [1,28,29]. Thus, afﬁnity
selection of peptide ligands from phage-displayed
libraries was instrumental in correctly predicting the
interacting proteins of intersectin.
Once peptides that bind to another protein have
been identiﬁed via phage-display, they can be used
in two different avenues of drug discovery. First,
the peptides can be used to validate the biological
importance of a particular protein-protein interac-
tion in the cell. For example, electroporation of
peptide ligands to the SH3 domain of Lyn can
block rat mast cell activation [26], and overexpres-
sion of peptide ligands to the E. coli Prolyl-tRNA
synthetase, which were also inhibitors of charging
activity in vitro [12], prevented bacterial growth
in vivo [27]. Thus, peptide ligands can be used to
validate particular proteins in cells as being ‘good’
drug targets. Second, it is possible to use the
peptides in displacement assays in which libraries
of natural products and small organic chemicals are
rapidly screened for inhibition of particular protein-
protein interactions [15,11,12]. Thus, in addition to
the great utility of phage-displayed peptide ligands
in mapping protein-protein interactions, they are
invaluable in drug discovery efforts.
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